Fig. 2From: SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialProgression free survival according to treatment arm. The continuous line indicates the standard arm (a), the dashed line the experimental arm (b)Back to article page